EUVIMEDEUVIMED entdecken
Crossref

Improved calreticulin nanobody by framework engineering

Logan Mavar, Mikhail Pavlenok, Avraneel Paul, Lucinda Hall iD, Benjamin M Larimer, Michael Niederweis iD

Protein Engineering, Design and Selection · 09.01.2026 · 39

DOI: 10.1093/protein/gzag030 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Protein Engineering, Design and Selection, online erschienen am 21.10.2026. Verfasst von Logan Mavar und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, University of Alabama at Birmingham, Birmingham, AL 35294, United States. Hauptthemen laut MEDLINE: Calreticulin, Single-Domain Antibodies, Protein Engineering. Die Arbeit nennt 46 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Calreticulin is an emerging cancer biomarker, but current detection methods rely on expensive monoclonal antibodies that suffer from inefficient protein production, pharmacokinetic challenges and poor tissue penetration. Cal3, a calreticulin-specific nanobody, was constructed by replacing the complementarity-determining region 2 (CDR2) of a soluble, clinically validated HER2 nanobody with a calreticulin-specific CDR2 isolated from a phage display library. However, the poor solubility and low yield of Cal3 limit its usefulness. In this study, we engineered the CALR nanobody 02 by adapting the core of Cal3 to a consensus framework sequence for stable nanobodies. CALR-Nb02 was purified with a 240-fold higher yield as a soluble protein with an increased thermal stability and a five-fold higher calreticulin binding affinity (KD: 25 nM) compared with Cal3. These results reveal a strategy for quickly altering the specificity of a stable nanobody and provide an improved calreticulin-binding reagent for future diagnostic, imaging, and therapeutic applications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CalreticulinSingle-Domain AntibodiesProtein EngineeringHumansAmino Acid SequencePeptide LibraryProtein BindingProtein Stability

Stichwörter der Autor:innen

biomarkerscancerdetectionprotein binderssingle-domain antibodies

Substanzen

CalreticulinSingle-Domain AntibodiesPeptide Library

Autor:innen und Institutionen

  • Department of Microbiology, University of Alabama at Birmingham, Birmingham, AL 35294, United States.
  • Department of Radiology, University of Alabama at Birmingham, Birmingham, AL 35294, United States.
  • Department of Surgery, University of Alabama at Birmingham, Birmingham, AL 35233, United States.
  • O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL 35233, United States.

ORCID-Profile: Lucinda Hall, Michael Niederweis

Zitieren

APA

Mavar, L., Pavlenok, M., Paul, A., Hall, L., Larimer, B. M., & Niederweis, M. (2026). Improved calreticulin nanobody by framework engineering. Protein Engineering, Design and Selection, 39. https://doi.org/10.1093/protein/gzag030

Vancouver

Mavar L, Pavlenok M, Paul A, Hall L, Larimer BM, Niederweis M. Improved calreticulin nanobody by framework engineering. Protein Engineering, Design and Selection. 2026;39. doi:10.1093/protein/gzag030

BibTeX
@article{Mavar2026,
  author = {Mavar, Logan and Pavlenok, Mikhail and Paul, Avraneel and Hall, Lucinda and Larimer, Benjamin M and Niederweis, Michael},
  title = {Improved calreticulin nanobody by framework engineering},
  journal = {Protein Engineering, Design and Selection},
  year = {2026},
  volume = {39},
  doi = {10.1093/protein/gzag030}
}
Kostenlos starten →